Ralf Kuriyel, Senior VP, R&D at REPLIGEN CORP (RGEN), sold 2,075 shares at $190.06 ($398K) on 2021-03-04, disclosed to the SEC on 2021-03-08.
Seasonal sale ($398k) by Senior VP, R&D — this insider has traded RGEN in March in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $190.06 | 700 | $133K | 33.4% |
| 2 | $191.20 | 600 | $115K | 28.8% |
| 3 | $192.24 | 350 | $67K | 16.9% |
| 4 | $194.30 | 25 | $5K | 1.2% |
| 5 | $196.23 | 400 | $78K | 19.7% |
| Total | $192.00 avg | 2,075 |
| $398K |
| 100% |
| Filing → |
| RGEN | SELL | 2024-03-12 | $1.4M | — | Filing → |
| RGEN | SELL | 2022-08-12 | $2.3M | — | Filing → |
| RGEN | SELL | 2021-09-02 | $2.3M | — | Filing → |